Beyond Pilot: Unlocking Pharma 4.0 Success

Beyond Pilot: Unlocking Pharma 4.0 Success

Getting your Trinity Audio player ready...

Life science manufacturers are trying to become more agile and use information more effectively to drive their businesses. Yet the pressures in life science manufacturing are unique. Products have a significant impact on human life, tolerances are tight, regulatory requirements are increasing, and there is a high cost of failure.

These pressures make implementing new technology more challenging than general industrial verticals. There are constraints from existing processes, tools, and IT systems that must be considered when deploying new systems, including:

• Architectural fragility previously introduced by custom code and point-to-point integrations
• Lack of data standardization and normalization across machinery
• Massive data lakes of machine data without context
• Siloed laboratory, maintenance, and supply chain data

These constraints create an agility paradox, as processes need to be closely controlled, while analytics requires a real-time, iterative approach. These constraints can also lead to rising and unpredictable cloud ingestion and processing costs and inefficient use of human resources. As such, many life science manufacturers are still struggling to scale their Pharma 4.0 use cases beyond pilot.

Yet there are life science manufacturers who are seeing success and leading the way, including Catalent and Alcon. Both have used an Industrial DataOps approach to contextual data, reduce manual processes for data collection and analysis, minimize one-off integrations, and ultimately build a comprehensive, flexible data infrastructure.

Catalent

Catalent is a contract development and manufacturing partner for personalized medicine, drugs, and consumer brands.

Catalent faced a multifaceted challenge with their bioreactor data. They wanted to model data from their bioreactors to make it accessible in their Unified Namespace (UNS), but the data lacked the context and format necessary to be usable by data consumers. To give their data context, they relied on a manual process in which data scientists spent time labeling data.

To prepare data for the UNS and reduce manual efforts, Catalent adopted an Industrial DataOps approach. This approach has enabled them to build a replicable model that added the context needed to make their data fit the ISA-95 format of the UNS, freeing their data scientists from almost all manual labeling.

Increased productivity and value generation can be difficult to quantify, but Chris Demers, Global Lead for Plant Data and Analytics at Catalent, clearly sees the value. Chris advises that manufacturers measure ROI in digital infrastructure investments by calculating the time savings achieved by eliminating manual data entry. This time savings frees up highly skilled personnel to focus on critical thinking and problem-solving and ultimately do more with less.

Alcon

Alcon is a pharmaceuticals device company specializing in eyecare products, including contact lenses and ocular surgical equipment.

Like many manufacturers, Alcon was struggling to scale their Industry 4.0 use cases beyond pilot. The company adopted an Industrial DataOps approach to build an architecture designed for scale.

This approach also allowed them to first process their data on-premises to reduce cloud ingestion costs and contextualize the data closer to the data source and domain expert. With their newly standardized data, Alcon was able to launch a predictive maintenance program that they could easily adapt to work on additional sites in weeks rather than years.

To justify these investments, John Patanian, Data Analytics Manager at Alcon, provided the following advice:

• Tie infrastructure investments to other key performance indicators (KPIs) to justify funding requests.
• Demonstrate how infrastructure investments contribute to improved plant performance and other measurable outcomes. For Alcon, this meant highlighting three key areas: Cost reduction through optimization, increased efficiency leading to value-added activities, and improved productivity.

This approach has enabled Alcon to better develop future funding requests for new use cases aimed at increasing efficiency and lowering costs.

Industrial DataOps for Pharma 4.0

Catalent and Alcon have both implemented an Industrial DataOps platform as a core element of their architecture. This platform has been designed specifically for industrial data modeling, delivery, and governance.

Based on learnings from these companies and other life science manufacturers, I recommend the following:

• Measure your digital maturity. It is critical to understanding your current state and guiding your data architecture evolution.
• Find an Industrial DataOps solution that can conform to your existing infrastructure. This is ideal for highly regulated industries like the life sciences, as it will minimize interruptions to critical compliance processes.
• Work with software solutions that provide scalability and maintainability. This will enable rapid deployment and access to information across the enterprise, including vendors and contract manufacturers.
• Work across departments to design a data architecture that’s reusable, including asset model portability.
• Define data usage and payloads before moving data to the cloud. Pre-process data before sending it to the cloud to ensure it is in a usable format.
• Define the right balance between edge and cloud computing for your unique organization, with data being sourced, processed, and analyzed in different locations depending on user needs and latency requirements.

To learn more about Catalent and Alcon’s approaches to building a scalable data architecture, watch the panel discussion or download this ABI Insight report from ABI Research.

About the author

Torey Penrod-Cambra is the Chief Communications Officer of HighByte, focused on the company’s messaging strategy, market presence, and ability to operationalize. Her areas of responsibility include marketing, public relations, analyst relations, investor relations, and people operations.